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Abstract: Renal cell carcinoma (RCC) remains a significant health concern that frequently 
presents as metastatic disease at the time of initial diagnosis. Current first-line therapeutics for 
the advanced-stage RCC include antiangiogenic drugs that have yielded high rates of objective 
clinical response; however, these tend to be transient in nature, with many patients becoming 
refractory to chronic treatment with these agents. Adjuvant immunotherapies remain viable 
candidates to sustain disease-free and overall patient survival. In particular, vaccines designed 
to optimize the activation, maintenance, and recruitment of specific immunity within or into the 
tumor site continue to evolve. Based on the integration of increasingly refined immunomonitoring 
systems in both translational models and clinical trials, allowing for the improved understand-
ing of treatment mechanism(s) of action, further refined (combinational) vaccine protocols are 
currently being developed and evaluated. This review provides a brief history of RCC vac-
cine development, discusses the successes and limitations in such approaches, and provides a 
rationale for developing combinational vaccine approaches that may provide improved clinical 
benefits to patients with RCC.
Keywords: renal cell carcinoma, vaccines, immunotherapy, combinational therapy, cellular 
immunity
Introduction: immunotherapy  
for renal cell carcinoma
Renal cell carcinoma (RCC) accounts for approximately 3% of all cancers in adults, 
with metastases identified in 20%–30% of patients at the time of diagnosis. Metastatic 
RCC, if left untreated, has a 5-year disease-free survival rate of 2%–11%.1 Following 
nephrectomy, conventional treatments with standard chemotherapeutic agents, hor-
mones, and radiotherapy have shown minimal success. This has prompted extensive 
evaluation of alternate treatment strategies, including immunotherapies, in the adjuvant 
and advanced disease settings.
Optimism for the use of biological response modifiers and vaccines has been 
buoyed by past findings, which suggest that, like melanoma, RCC progression and 
regression may be regulated by immunologic mechanisms.2–5 Patients with RCC 
exhibited a low but significant incidence of spontaneous regression,6,7 and patients 
under chronic immunosuppression regimens to retain kidney allografts displayed an 
increased risk of developing RCC.8 The degree of tumor infiltration by lymphocytes has 
been used as a prognostic indicator for patient survival.9,10 In particular, T cells of the 
type-1 polarization profile (ie, capable of producing interferon [IFN]-γ and mediating 
the cytotoxic death of RCC tumor cells) and proliferative potential11,12 have proven 
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to represent primary immunologic mediators of objective 
 clinical responses (OCRs).
However, patients with RCC are frequently character-
ized with a state of “immune dysfunction”,13–16 where type-1 
responses directed against tumor-associated antigens are 
muted in comparison with type-2 (normally associated 
with antibody production and allergic reactivity) and/or 
T-regulatory (Treg) responses, which are immunosuppres-
sive in nature.17–20 Furthermore, when the responses can be 
identified, type-1 anti-RCC T cells may be proapoptotic under 
a chronic state of stimulation with specific tumor antigens in 
patients with cancer.21,22
Rationale for RCC vaccines
As depicted in Figure 1, therapeutic normalization of type-1, 
antitumor T-cell-mediated immunity in patients with RCC 
requires one or more of the following processes to occur: 
(1) existing tumor antigen-experienced T cells exhibit-
ing anergy or nontype-1 functional polarization need to 
be reactivated or retrained to become type-1 polarized; (2) 
the survival and functionality of existing type-1 T cells 
must be extended; (3) new type-1 effector cells must be 
“primed” from the naive cohort of T cells (a process that may 
require the  “breaking” of operational tolerance); (4) effec-
tive trafficking of renal cell carcinoma – associated antigen 
(RCCAA)-specific T cells to the tumor microenvironment 
(TME); and/or (5) blunting of regulatory T cells (Treg) that 
suppress effector T-cell activation, function, and durability. 
Each of these immunologic end points may be theoretically 
achieved via the implementation of tumor-specific vac-
cines that contain and/or condition antigen-presenting 
cells (APCs) in situ to assume type-1 function (typically 
associated with the ability of APCs to differentially secrete 
interleukin [IL]-12 vs IL-10).23–25 Reports have shown that 
type-2 “memory” T-cell responses (ie, characterized by 
strong IL-4 and IL-5 production) may be repolarized toward 
type-1 immunity in vitro by (re)stimulation with antigen-
pulsed dendritic cells (DCs) that were preconditioned with 
proinflammatory cytokines, toll-receptor ligands, and other 
costimulatory adjuvants.23,26,27 In humans, type-1 effector 
T cells have exhibited extended survival, function, and 
conversion into the memory cells when provided signals 
RCC-Induced immune deviation Preferred immunologic outcomes
(Pre-vaccine) (Post-vaccine)
Anergic Pro-apoptotic Non-type-1
functional
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Figure 1 Paradigm for effective renal cell carcinoma (RCC) vaccines. Antitumor T cells in patients with RCC are frequently anergic, hyporesponsive, or they may mediate 
functions that are nonprotective. T effector (Te) and memory (Tm) cells (cumulatively indicated as Te/m) may also be prone to apoptotic death based on conditioning by 
tumor cells or their elaborated products in vivo. Naive (T0) antitumor T cells may be rendered nonresponsive or exhibit specificities against “subdominant” RCC-associated 
antigens (RCCAAs) or epitopes that have failed to become activated productively. Furthermore, the vitality and function of antitumor T cells may be inhibited by regulatory 
T cells and myeloid-derived suppressor cells (MDSCs), particularly in the tumor microenvironment (TMe). effective vaccine formulations would at least partially correct 
such defects by (re)activating Te/m and promoting their extended survival and delivery into the TMe. importantly, given some plasticity in functional T-cell polarization, effective 
RCC vaccines may promote a conversion of nontype-1 T-cell responses towards type-1 immunity, which has been commonly associated with improved clinical prognosis. 
Such vaccine-induced repolarization in T-cell function may foster the breaking of operational tolerance against additional RCCAAs and the cross-priming of a broadly 
reactive antitumor T-cell repertoire. if sustained (through booster vaccination), this vaccine-initiated T-cell response may extend time to disease recurrence or progression 
and overall patient survival.
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from CD16+ monocyte-derived DCs.28 Furthermore, type-1 
polarized or conditioned DCs appear superior to alternate 
APC types in their capacity to activate and drive naive T-cell 
differentiation into type-1 CD4+ and CD8+ T effector cells 
in vitro and in vivo.23,29,30 Although much of these data have 
been developed translationally in the context of cell (ie, 
DC-based) therapeutics, it would also be predicted that cell-
free vaccine formulations including the appropriate tumor 
antigens and conditioning adjuvants would activate APC in 
situ with similar type-1-polarizing potential.31–33
RCCAA and vaccine construction
Vaccines designed to promote specific adaptive immunity 
against RCC have been traditionally grouped into 4 general 
categories. One type of tumor vaccine is RCC cells them-
selves (either autologous or allogenic cells that express 
unique and shared tumor-associated antigenic proteins). More 
than 20 years ago, Miller et al34 trialed autologous RCC tumor 
cells using Cryptosporidium parvum as an adjuvant. Later, 
Tani et al35 and others modified the autologous tumor cell vac-
cine by using granulocyte macrophage-colony- stimulating 
factor (GM-CSF) or other inflammatory cytokines as adju-
vant. Thereafter, others used genetically modified patient 
tumor cells that expressed inflammatory cytokines, including 
GM-CSF, IFN-γ, and IL-2.36 Another tumor vaccine formu-
lation is represented by RCC-APC fusion hybrids, which 
generate APCs that are capable of expressing RCC gene 
products and presenting their derivative peptide epitopes to 
T cells. Avigan et al37 were one of the few groups that used 
this strategy to treat patients with RCC. They fused autolo-
gous tumor cells to DCs from normal donors using serial 
electrical pulses. Another approach involves RCC-derived 
total mRNA or cDNA (encoding the complete repertoire of 
RCCAA). Although most published work using these vac-
cines has been limited to preclinical models,38,39 Su et al40 
used autologous DCs transfected with total RCC RNA. More 
recently, several laboratories have been moving toward a 
more specified vaccine formulation using peptides, protein, 
mRNA, or cDNA derived from or encoding one or more 
molecularly defined RCCAAs (Table 1). Wierecky et al41 and 
Bleumer et al42 have vaccinated RCC patients with mucin 
(MUC1) and carbonic anhydrase (CA-IX) peptides, respec-
tively, loaded on to autologous DCs. The clinical outcomes 
associated with these various vaccine formulations will be 
discussed later in this review.
A myriad of genetic aberrations can potentially develop 
within the evolving heterogeneous RCC lesion over many 
months to years under immune selective pressure. The first 
3 categories of vaccines cited earlier theoretically provide 
the greatest variety of RCCAAs, which promote the broadest 
antitumor T-cell repertoire, when applied in the context of a 
vaccine. In vaccines based on whole tumor cells, tumor-APC 
hybrids, and/or tumor-derived mRNA or cDNA, RCCAAs 
derived from mutant proteins with alternate open reading 
frames (ORFs), antisense transcripts, or unique protein-
splicing events (Table 1) will be incorporated without know-
ing the identity of the RCCAA. However, these approaches 
have limitations from an immunologic perspective. Complex 
mixtures of unknown RCCAA may merely reinforce an 
existing, yet failing, immune repertoire given the immune 
dominance of certain RCCAAs over others. Competition 
by hundreds or thousands of peptide epitopes for loading 
into major histocompatibility complex (MHC) molecules 
expressed by (cross-presenting) APCs in vivo could prevent 
attaining immunogenic quantities of RCCAA peptides. These 
types of vaccines would also introduce an array of immunsup-
pressive genes and gene products (ie, IL-10, transforming 
growth factor [TGF]-β, B7-H1, indoleamine 2,3-dioxygenase 
[IDO], etc) into the vaccine site that may negate the immu-
nostimulatory potential of the treatment.
A less-dynamic, but better-controlled, vaccine approach 
involves the use of molecularly defined RCCAAs identified 
by tumor cell or tumor “genome-” or “proteome-based” 
approaches. Such a formulation reduces the effects of con-
founding immunosuppressive signals or competing ligands 
for MHC presentation. Among the many RCCAAs identified 
and defined as targets for T-cell recognition over the past 
10–15 years, most of these gene products represent proteins 
that are 1) nonmutated, 2) frequently overexpressed by tumor 
vs normal kidney tissue, and 3) upregulated as a consequence 
of the hypoxic or hypomethylating conditions prevalent 
in the TME (Table 1). The conditional and/or preferential 
(over)expression allows for the differential expression of 
antigenic peptides in MHC complexes expressed by tumor 
cells vs normal cells. This property of RCCAAs encourages 
the development of therapeutic vaccines capable of eliciting 
antigen-specific T effector cells that may strategically eradi-
cate tumor cells without manifesting pathologic autoimmune 
correlates.
Several well-defined RCCAAs have been (or could be) 
implemented in phase I/II vaccine trials for patients with 
RCC. A partial list of more than 30 such candidates is pro-
vided in Table 1. Nearly 2 dozens of these gene products 
were reported to be (over) expressed in the majority of RCC 
specimens evaluated, making them tenable candidates for 
inclusion in a “general” vaccine for treating patients with 
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RCC. Notably, those RCCAAs that may function as general 
RCCAAs for use in vaccines include survivin, an inhibitor 
of apoptosis whose expression is correlated with poorly 
differentiated, advanced-stage RCC;43 the receptor tyrosine 
kinases (RTKs) EphA2, epidermal growth factor receptor 
(EGFR), c-Met, and Her2/neu;44,45 MUC1;46 CA-IX, also 
known as G250;47 and the oncofetal antigen 5T4.48
Of the aforementioned RCCAAs, CA-IX and 5T4 are 2 
of the more frequently overexpressed RCC markers. CA-IX 
overexpression in RCC is associated with a defect in the Von 
Hippel-Lindau (VHL) tumor suppressor gene via activation 
of hypoxia-inducible factor-α (HIF-α).49 In conjunction with 
regulation by VHL-HIF, CA-IX expression is also driven by 
the methylation status of the C9 gene, as the C9 promoter 
has been reported to be hypomethylated in all CA-IX+ RCC 
cell lines and to be hypermethylated in all CA-IX− RCC cell 
lines.50 CA-IX is beginning to be exploited as a therapeutic 
target for RCC only now.51 Only within the last few years 
has an appropriate animal model been established to study 
CA-IX-expressing tumors, using human CA-IX-transduced 
murine RCC cells.52 Recently Bauer et al53 published promis-
ing results on a G250 – tumor necrosis factor fusion antibody 
administered with IFN-γ to RCC xenograft-bearing nude 
mice; however, no CA-IX-based therapies have yet made it to 
Table 1 RCC-associated antigens (RCCAAs) recognized by T cells
Antigen Antigen  
category
Frequency of  
expression among 
RCC tumors (%)
CD8+ T-cell recognition:  
patients with HLA class I 
allele(s)
CD4+ T-cell recognition:  
patients with HLA class II  
allele(s)
References
Survivina ML 100 Multiple Multiple 114
OFA-iLR OF 100 A2 NR 115, 116
iGFBP3a,b ML 97 NR Multiple 117, 118
ephA2a ML .90 A2 DR4 17, 44, 119
RU2AS Antisense  
transcript
.90 B7 NR 120
G250 (CA-iX)a,b RCC 90 A2, A24 Multiple 47, 51
eGFRa,b ML 85 A2 NR 121, 122
HiFPH3a ML 85 A24 NR 123
c-Meta ML .80 A2 NR 124
wT-1a ML 80 A2, A24 NR 125–128
MUC1a,b ML 76 A2 DR3 46, 129, 130
5T4 ML 75 A2, Cw7 DR4 54, 131–133
iCe aORF 75 B7 NR 134
MMP7a ML 75 A3 Multiple 117, 135, 136
Cyclin D1a ML 75 A2 Multiple 117, 137, 138
HAGeb CT 75 A2 DR4 139
hTeRTa,b ML .70 Multiple Multiple 140–142
FGF-5 Protein splice  
variant
.60 A3 NR 143
mutvHLa,b ML .60 NR NR 144
MAGe-A3b CT 60 Multiple Multiple 145
SART-3 ML 57 Mulitple NR 146–149
SART-2 ML 56 A24 NR 150
PRAMeb CT 40 Multiple NR 151–154
p53a,b Mutant/wT ML 32 Multiple Multiple 155, 156
MAGe-A9b CT .30 A2 NR 157
MAGe-A6b CT 30 Multiple DR4 18, 158
MAGe-D4b CT 30 A25 NR 159
Her2/neua ML 10–30 Multiple Multiple 45, 160–164
SART-1a ML 25 Multiple NR 165–167
RAGe-1 CT (ORF2/5) 21 Multiple Multiple 151, 157,  
168, 169
TRP-1/gp75 ML 11 A31 DR4 151, 170–172
Note: A summary is provided for RCCAAs that have been defined at the molecular level. RCCAAs are characterized with regard to their antigen category, their prevalence 
of (over) expression among total RCC specimens evaluated, whether RCCAA expression is modulated by hypoxia or tumor DNA methylation status, and which HLA class i 
and class ii alleles have been reported to serve as presenting molecules for T-cell recognition of peptides derived from a given RCCAA. aHypoxia-induced. bHypomethylation-
induced.
Abbreviations: CT, cancer-testis antigens; ML, multilineage antigens; NR, not reported; OF, oncofetal antigen; aORF, altered open reading frame; ORF, open reading frame; 
RCC, renal cell carcinoma; wT, wild type.
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clinic. The heavily glycosylated transmembrane protein 5T4 
is overexpressed by RCC tumor cells.54 In a phase II trial for 
RCC, a recombinant fusion protein composed of a modified 
form of staphylococcal enterotoxin A (SEA) linked to mouse 
Fab specific for 5T4 has exhibited antitumor efficacy, albeit 
in the context of moderate toxicity.55 Therapeutic viral vec-
tors have also been used as a vaccination strategy, one being 
TroVax, a highly attenuated vaccinia virus, modified vaccinia 
ankara (MVA), which encodes the human 5T4 antigen. In 
a phase II trial, TroVax with IL-2 appeared to confer some 
clinical advantage, with some patients showing disease sta-
bilization and an improved ratio of CD8+ effectors to Treg 
cells.56,57 Patients cotreated with TroVax and IFN-α, however, 
did not show significant clinical improvement, despite having 
5T4-specific antibody and/or cellular responses.58,59
In most cases, RCCAA-derived peptide epitopes rec-
ognized by CD8+ and/or CD4+ T cells have been identified. 
Such peptides may be used in vaccines for treating patients 
with relevant human leukocyte antigen (HLA) class I or 
II tissue types, which are required for presenting a given 
peptide epitope to the immune system. Recently, Rahma 
et al33 published results from a pilot study testing a mutant 
VHL peptide vaccine customized to each patient’s specific 
mutation and HLA haplotypes, with 80% of the treated 
patients exhibiting specific immune responses. In Table 1, 
we list the HLA allelic molecules to which known RCCAA 
peptides bind and are recognized by CD4+ and CD8+ T cells. 
These peptides are also applicable in immune monitoring of 
specific in vitro T-cell responses of patients being treated 
with any form of vaccine or immunotherapy. Vaccination 
against a single peptide can potentially promote “epitope 
spreading” in the evolving antitumor CD8+ T-cell repertoire 
based on cyclic and longitudinal cross-priming events within 
(tumor-draining) lymph nodes.41,60,61 Additionally, several 
peptides (from one or more RCCAAs) can be constructed 
into a single vaccine formulation using mixtures of peptides 
or an extended “bead-on-a-string” protein construct in which 
multiple epitopes are expressed in tandem.62–64 Such formula-
tions focus the T cell on a more limited, but potentially more 
effective, cohort of RCCAA epitopes that may be immuno-
logically subdominant and/or ignored under standard condi-
tions, thereby unveiling a previously undertapped population 
of antitumor effector cells.
RCC vaccines in the clinic
Most of the clinical vaccine trials in patients with RCC 
performed till date have involved the use of whole tumor 
cells, tumor lysates, or the fusion of RCC cells with DCs.65,66 
Vaccine formulations based on specific RCCAAs (protein, 
cDNA) or their derivative (MHC-presented) peptides have 
lagged behind due to the comparatively recent molecular 
identification of the applied RCCAA. Rather than providing 
a traditional tabulated summary of the data resulting from 
such trials, we provide a schematic diagram of trial outcomes 
based on the clinical (primary) and immunologic (secondary) 
end points defined in these protocols (Figure 2). We have 
further delineated vaccines based on the type of RCCAA 
utilized in each trial.
Despite recent discussions stating that immunotherapies 
should not be evaluated based on the “acute” response criteria 
(Response Evaluation Criteria in Solid Tumor [RECIST]) 
defined for chemotherapeutic agents because immunothera-
pies may depend on the gradual build up of adaptive immu-
nity over a protracted period of time,67,68 virtually all reported 
RCC vaccine trials have still done so. Hence, in Figure 2, we 
have depicted OCR frequencies based on partial responses 
(PRs), complete responses (CRs), or stabilization of disease 
(SD) per RECIST criteria as reported by the primary inves-
tigators. The consensus of such information suggests that 
current RCC vaccines are generally safe and well tolerated,69 
but are curative in only a very minor subset of treated patients. 
Although PRs increase in frequency somewhat after vac-
cine treatment, the major benefit of these cancer vaccines is 
reflected in many patients who exhibit stable disease, leading 
to increased progression-free and overall survival when com-
pared with control groups.69–72 Notably, each of the various 
vaccine formulation categories listed yielded similar clinical 
impact based on RECIST criteria (Figure 2), with roughly 
50% of treated patients exhibiting stable disease, 20% show-
ing partial response, and ,20% developing CRs.
Since these represent immunotherapies rather than 
chemo- or radiotherapies, immunologic end point analyses 
are critical for determining the biological efficacy of these 
approaches and how such strategies may be improved based 
on our current understanding of RCC immunobiology. In this 
regard, the diverse array of RCC vaccine trials performed 
over the past 15 years has implemented a number of immune 
assessment assays to determine specific immune response 
to active vaccination, including analyses of patient tumor-
specific T-cell responses in vitro (TRIV) and delayed-type 
hypersensitivity (DTH) responses to vaccine components 
in vivo. Assays for TRIV have dramatically evolved over the 
past decade, with established proliferation (ie, 3H-thymidine 
incorporation) and cytokine (ie, enzyme-linked immunosor-
bent assay [ELISA]) assays now being supplanted by methods 
capable of discerning the frequency and/or  functionality of 
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clonal T-cell responses (ie, cytokine [IFN-γ] enzyme-linked 
immunosorbent spot [ELISPOT] assays, intracellular staining 
of T cells for cytokine [predominantly IFN-γ] production and 
reactivity of T cells with fluorescently-labeled, recombinant 
MHC-tumor peptide multimers). The merits and perceived 
weaknesses of these various methods have been well dis-
cussed in the past.73–75
Here, we provide a sample of the reported clinical trial 
data, which strongly support the capacity of RCC vaccines 
(implementing each of the 6 major formulations shown in 
Figure 2) to promote an increase in RCC-specific T-cell 
responsiveness. Although the frequency of immunologi-
cally responsive patients was highly variable within a given 
treatment type, the majority of treated patients in many 
cases exhibited detectable increases in TRIV at some point 
after vaccination. Similarly, DTH analyses suggest that 
RCC vaccines have been generally competent to promote 
tissue inflammation at sites of vaccination (mediated by 
type-1 T cells, as shown in Figure 2). However, detectable 
TRIV and DTH as determined by current methods, even at 
high percentages, do not seem to directly correlate with the 
clinical outcome.
The general consensus regarding the immunologic moni-
toring of cancer patients receiving immunotherapy is that 
more than one assay system should be applied to monitor 
the changes in a patient’s T-cell immune response to specific 
antigens. However, there are currently no acknowledged 
immunologic surrogate markers associated with OCR in 
treated cancer patients. Nevertheless, a number of vaccine 
trials have reported that 1) patients exhibiting OCR do typi-
cally fall within the cohort of patients exhibiting increased 
specific T-cell responses after vaccination;41,76 2) clinical 
benefit may be associated with an increased ratio of CD8+ 
T effector cells vs Treg cells;56,57 3) patients exhibiting OCR 
may have an expansion in their functional – cell repertoire 
against RCCAA specificities that were not included in the 
%
 P
at
ie
n
ts
 e
xh
ib
it
in
g
 r
es
p
o
n
se
V
ac
ci
n
e
co
m
p
o
n
en
ts
Im
m
u
n
e
m
o
n
it
o
ri
n
g
C
lin
ic
al
 
im
p
ac
t
100
RCC
(323)
Engineered
RCC (201)
RCC Ag
(79)
DC/RCC
Fusion (89)
80
60
40
20
0
100
80
60
40
20
0
Irradiated
AutoRCC or
Purified RCC
plasma
membrane
+/- C. parvum,
+/- C. albicans,
+/- BCG +/- IFN
+/- GM-CSF
Irradiated
AutoRCC or
transfected
with cDNA
encoding
B7.1, GM-
CSF, IL-2,
IL-7 and/or 
tagPGRP5 +/-
rIL-2 +/- OGN
Trovax,
RCC HSP
Complexes
(Vitespen),
CAIX
peptide,
WT1
peptide +/-
IFA, +/-
Montanide,
+/- IL-2, +/-
IFN
AutoRCC 
or Allo RCC
fused with
AlloDC or
AutoDC
+/-IL-2
AutoRCC 
+Allo RCC
or
AlloDC or
AutoDC
+/-IL-2
AutoDC +  
peptides (CA-
IX,MUC1,
telomerase,
survivin) +/-
KLH +/- PADRE
CR PR SD CR PR SD CR PR SD CR PR SD CR PR SD CR PR SD
D
TH
TR
IV
D
TH
TR
IV
D
TH
TR
IV
D
TH
TR
IV
D
TH
TR
IV
D
TH
TR
IV
DC + RCC
Lysate (117)
DC + RCC
Peptides (95)
Figure 2 Renal cell carcinoma (RCC) vaccine trials: summary of clinical and immunologic monitoring results. Phase i/ii clinical trials were performed in patients with RCC using 
one of the six indicated types of RCC-associated antigens (RCCAAs), with the cumulative number of patients treated with a given modality indicated in parentheses. ReCiST 
criteria were applied to define patient response to therapy: CR, complete response; PR, partial response; SD, stable disease. The bottom panels show the components used 
in individual clinical trials. Data are only summarized from published trials in which coordinate immune monitoring for specific T-cell reactivity post- vs prevaccination was 
performed. immune monitoring was performed by assessing T-cell responses in vitro (TRiv) using proliferation or cytotoxicity assays, or via the analysis of iFN-γ production by 
T cells using intracellular staining (in concert with flow cytometry), ELISA or ELISPOT assays. Alternatively, type-1 T-cell responses were deduced based on cutaneous delayed 
type hypersensitivity (DTH) responses to vaccines in vivo. We report the percentage of treated patients exhibiting specific clinical impact outcomes and increases in specific 
T-cell responses based on the immune monitoring criteria established for a given protocol. Each filled circle represents the data reported for an individual clinical trial.
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vaccine formulation (ie, “epitope spreading”); and (4) patient 
pretreatment levels of type-1 chemokines, such as IP-10, in 
serum may portend to better clinical outcome.72 Data col-
lected from animal tumor models have shown that the effec-
tiveness of a given vaccine or immunotherapy was linked to 
the recruitment of RCCAA-specific T effector cells into the 
TME via CXCR3 ligands, such as IP-10/CXCL10. Interest-
ingly, in vitro studies have shown that IP-10 may promote 
apoptosis of CXCR3B+ vascular endothelial cells (VECs) in 
the TME, implicating the role of at least this particular type-1 
chemokine in regulating angiogenesis.77
Combinational RCC vaccines: 
rationale and past efforts
Thus, existing RCC vaccine platforms increase the frequency 
of circulating anti-RCC T cells (and antibodies) based on 
immunological readouts established as secondary end points 
in clinical trials performed to date. However, few things 
remain completely unclear: (1) what threshold of such antitu-
mor T cells must be reached to be biologically active against 
tumor? (2) what (poly)functionality and operational avidity 
should these T effectors exhibit in the TME (or elsewhere) 
to promote optimal antitumor impact? (3) do optimized vac-
cines include a risk of autoimmune pathology by inducing 
high-avidity T effector cells capable of recognizing normal 
tissues expressing low levels of “self ” RCCAA? or (4) would 
even the most immunostimulatory approaches be dampened 
via normal compensatory mechanisms as bursts in Treg num-
bers have been reported in certain RCC vaccine trials?72,78 
If “epitope spreading” in the T-cell repertoire is indeed a 
requisite to achieve and maintain objective clinical benefits, 
it will also be critical to normalize DC function within the 
TME. Specifically, it will be important to foster the ability 
of these APCs to effectively and reiteratively cross-prime 
antitumor T cells, some of which have to be retained for 
extended periods as memory cells.
Table 2 provides a partial list of additional immuno-
modulatory agents that could reinforce existing RCC vac-
cines by impacting the adaptive response at various levels 
suggested in Figure 1, namely, by (1) facilitating the process 
of cross-priming by normalizing APC function in the TME; 
(2) expanding the pool of treatment-induced antitumor 
T cells and improving their survival; (3) enhancing the func-
tion of these cells, including conversion into memory cells; 
(4) enhancing the recruitment of such T cells into the TME; 
and (5) reducing the suppression of T effector cells mediated 
by myeloid-derived suppressor cells (MDSCs) and Treg cells. 
Although we have indicated in a qualitative manner whether 
a given agent is likely to benefit or detract from a given 
biological parameter based on findings in the literature, it is 
important to acknowledge that no agent is perfectly suited to 
address all aspects in optimizing the therapeutic paradigm. 
Combinations of multiple agents may be necessary to yield 
complementary benefits. Realistically, such multicomponent 
vaccines may also have significant off-target toxicities, 
including the aforementioned autoimmune sequela that will 
require careful clinical monitoring. For instance, two of three 
RCC patients treated with autologous T cells engineered to 
express a high-avidity T cell receptor (TCR) reactive against 
the CA-IX (G250) RCCAA developed severe liver toxicity 
due to T-cell targeting of CA-IX expressed by bile duct 
epithelial cells.79
To a certain degree, the process of developing combina-
tional RCC vaccines has been initiated in phase I/II trials, 
based on the use of long-standing cytokines, such as IL-2, 
IFN-α, IFN-γ, and GM-CSF, as “adjuvants” to support the 
function of T cells and DCs. Other cotherapeutics such as 
ONTAK® (Ligand Pharmaceuticals, LaJolla, CA, USA) 
(anti-CD25), CTLA-4Ig, or all-trans retinoic acid (ATRA) 
have been used to alleviate the inhibitory action of Treg cells 
and/or MDSCs. However, only a limited number of prospec-
tive randomized trials have been conducted till date.
Fenton et al80 reported minimal impact of treating RCC 
patients with an irradiated, autologous tumor cell vaccine 
in concert with low- or high-dose of recombinant human 
interleukin (rhIL-2) vs the tumor vaccine alone in a phase I 
trial. This lack of benefit may relate, at least in part, to the 
well-known ability of rhIL-2 to support Treg expansion in 
treated patients.78,81 In a phase II study evaluating the efficacy 
of a MVA vaccine encoding the RCCAA 5T4 (TroVax) plus 
recombinant interferon α (rIFN-α), no benefit was observed 
in the cohort of patients receiving IFN-α cotherapy.59 Indeed, 
patients treated with vaccine + IFN-α tended to be less likely 
to exhibit antigen-specific TRIV and displayed shorter 
median progression-free survival and median overall survival 
when compared with patients treated with the vaccine alone. 
No rationale for this regulatory effect was suggested, but 
it is conceivable that the potent antiviral activity of IFN-α 
promotes more rapid viral clearance by activating neutral-
izing antibodies or antiviral T cells and actually limits the 
efficacy of booster vaccinations in patients receiving the 
TroVax vaccine.
In contrast to the aforementioned studies, patients with 
RCC receiving vaccines containing Newcastle virus-infected, 
irradiated, autologous RCC cells in combination with low 
dose of rhIL-2 and recombinant human interferon α2a 
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Table 2 Potential vaccine coimmunotherapeutics.
Cotherapeutic agent Expected impact on Teff vs suppressor cells
Teff priming Teff function Teff survival Teff (TME) Treg/MDSC References
Cytokines
 iL-2   +/−   (Treg) 173–175
 iL-7      (Treg) 176–178
 iL-12     − (Treg),  (MDSC) 179–181
 iL-15      (Treg)* 182, 183
 iL-18    ?  (Treg) 184–186
 iL-21     +/− (Treg) 187–190
 iFN-α     +/− (Treg) 175, 191–194 
 iFN-γ   −?   (Treg) 195–197
 GM-CSF      (Treg) 198–202
Coinhibitory antagonist
 CTLA-4   ?   (Treg) 203, 204
 PD1/PD1L      (Treg) 205–207
Costimulatory agonist
 CD40/CD40L      (Treg);  (MDSC) 208–211
 GiTR/GiTRL      (Treg);  (MDSC) 212, 213
 OX40/OX86      (Treg);  (MDSC) 214–219
 4-1BB/4-1BBL      (Treg) 220–224
TLR agonists
 imiquimod (TLR7)     ? 225–227
 Resiquimod (TLR8)    ? ? 228, 229
 CpG (TLR9)      (Treg) 230–232 
Antiangiogenic
 veGF-trap – – ? ? − 233
 Sunitinib   ?   (Treg/MDSC) 98, 100, 234
 Sorafenib    ?  (MDSC) 235
 Bevacizumab   ? ?  (MDSC) 236, 237
 Gefitinib (IRESSA) ? ? ? ? ? 238, 239
 Cetuximab ?  ? ? ? 240
mTOR inhibitors
 Temsirolimus/everolimus    ?  (Treg) 241
Treg/MDSC inhibitors
 iplimumab (CTLA-4)   ?   (Treg) 242, 243
 ONTAK (CD25) +/− +/− ? ?  (Treg) 244
 Anti-TGFβ/TGFβR      (Treg) 245–247
 Anti-iL10/iL10R    +/−  (Treg) 248, 249
 Anti-iL35/iL35R ? ? ? ?  (Treg) 250
 1-Methyl trytophan   ? ?  (MDSC) 251
 ATRA   ? ?  (Treg),  (MDSC) 90–93
Note: Agents that are currently or soon-to-be used in clinical trials are summarized with regard to their anticipated impact(s) on type-1 antitumor T cell (Te) activation, 
function, survival, and recruitment into the TMe. Additional anticipated effects of drugs on suppressor cells (Treg and MDSCs) are also summarized.
Key: , agent is expected to increase parameter; , agent is expected to inhibit parameter; +/-, minimal increase or decrease is expected in parameter as a consequence 
of treatment with agent; ?, unknown effect of agent on parameter.
Abbreviations: ATRA, all-trans retinoic acid; CTLA-4, cytotoxic T lymphocyte antigen 4; GiTR(L), glucocorticoid-induced TNF receptor (ligand); GM-CSF, granulocyte 
macrophage-colony-stimulating factor; iFN, interferon; iL, interleukin; MDSC, myeloid-derived suppressor cell; PD1/PD1L, programmed cell death 1 (ligand); TGF-β(R), 
tumor necrosis factor-β (receptor); TLR, Toll-like receptor; TMe, tumor microenvironment; Treg, regulatory T cell; veGF, vascular endothelial growth factor.
(rhIFN-α2a) appeared to display improved relapse-free and 
overall survival when compared with the cohort of patients 
receiving only the vaccine.82 Furthermore, combinational 
therapy benefit was also suggested in a study by Simons 
et al83 who performed a randomized, double-blinded phase II 
study comparing the efficacy of vaccines composed of control 
or GM-CSF cDNA-engineered autologous, irradiated RCC 
cells. In this trial, the GM-CSF-engineered vaccine was well 
tolerated with no dose-limiting toxicities or autoimmunity 
reported. It appeared to be capable of promoting superior 
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type-1 T-cell response to RCCAA (based on patient DTH 
readouts) when compared with vaccines composed of con-
trol tumor cells alone. Dannull et al have shown that partial 
depletion of Treg cells using ONTAK, an anti-CD25 antibody 
coupled to diphtheria toxin, conditions the patients with 
RCC for improved type-1 T-cell responses against autolo-
gous DCs transfected with mRNA isolated from autologous 
tumor cells.84 However, its impact on the clinical course 
was not reported. A recent phase I/II study by Holtl et al 
used allogenic DCs pulsed with autologous tumor lysates 
in conjunction with cyclophosphamide (CY) pretreatment 
to deplete Treg cells and provide “space” for homeostatic 
T-cell expansion. Results showed only a slight improvement 
in patients treated with CY, with a median overall survival 
of 23.2 months vs 20.3 months without CY.85
Combinational RCC vaccines: 
moving forward
A plethora of agents exist for consideration in the design 
of combinational vaccines (Table 2). Going forward, it will 
be crucial that all vaccine trials develop as randomized, 
prospective protocols that integrate secondary immuno-
logic end points. These immunological end points must 
determine the actual impact of the vaccine on RCC-specific 
T-cell responses over the duration of the study. This will 
be important not only to validate whether the perceived 
immunologic benefits of the combined approach are indeed 
met, but also to see how well they are met, so that future 
trials may be designed using agents that further augment 
or complement mechanisms currently believed to underlie 
optimal immunotherapeutic benefit.
In 2007, the NCI Immunotherapy Agent Workshop 
established a list of the top 20 (from among 124) agents that 
were considered by participants to have a high likelihood 
for efficacy in cancer therapy.86 Thirteen of these top 20 are 
cited in Table 2, including IL-15; anti-PD-1 (or anti-B7-H1); 
IL-12; anti-CD40 and/or anti-CD40L; IL-7, CpG, 1-MT, 
anti-4-1BB; anti-TGF-β; anti-IL10 or anti-IL10R; anti-GITR; 
anti-OX40; and resiquimod. As the merits of these agents 
are well delineated with regard to shaping, sustaining, and 
directing antitumor T-cell responses in the NCI Workshop 
report, we will focus our attention on a small cohort of these 
agents in the following paragraphs.
A major barrier to effective vaccine therapy in RCC is 
the immune regulatory component in cancer patients. As 
such, eradication or inhibition of Treg cells and MDSCs 
would promote vaccine efficacy. One mechanism that some 
groups have been targeting is CTLA-4 signaling of Treg 
cells.84 CTLA-4 blockade has been applied as a monotherapy 
for RCC, where it has been reported to yield partial clinical 
responses (PRs) in approximately 25% of treated patients 
with RCC for up to 18 months.87 However, autoimmune 
hypophysitis and colitis have been reported in patients with 
RCC receiving CTLA-4-blocking agents.88,89 Such toxici-
ties might be exacerbated by vaccine combinations and will 
require careful monitoring in prospective clinical trials.
It has recently been reported by multiple groups that 
ATRA can ablate the number and/or suppressive function 
of MDSCs, while augmenting the function of DCs isolated 
from patients with RCC resulting in improved type-1 
TRIV.90,91 Furugaki et al92 have also shown that ATRA 
serves as an effective adjuvant when combined with genetic 
immunization, promoting long-term survival in a murine 
promyelocytic leukemia model. However, ATRA has also 
been reported to regulate the balance between developing 
Treg vs Th17 cell responses in the CD4+ T-cell compart-
ment, favoring the Treg outcome.93 This seems to be based 
on signals mediated via nuclear retinoic acid receptor-α 
(RARα), making ATRA (or other RARα antagonists) a 
potential double-edged sword when considering the design 
of combinational RCC vaccines.
Intriguing candidates for integration into combina-
tion RCC vaccine design include small molecules, such 
as tyrosine kinase inhibitors (TKIs). Several clinical trials 
have utilized TKIs to inhibit various RTKs, such as vascular 
endothelial growth factor receptor (VEGFR), as an antian-
giogenic agent to treat RCC. One such TKI is sunitinib, 
which has exhibited pronounced (albeit transient) efficacy in 
phase I/II clinical trials as a first-line treatment for patients 
with RCC.94–96 Even though this drug was initially developed 
as an antiangiogenic agent, a series of very recent reports 
suggest that patients treated with sunitinib exhibit reductions 
in peripheral blood levels of MDSCs and Treg cell popula-
tions and normalized type-1 TRIV after mitogenic stimula-
tion.97–100 Murine tumor modeling suggests that sunitinib 
suppresses STAT3 activation101 and bolsters the efficacy 
of immunogenetherapy by promoting RCCAA-specific 
T effector cells and concomitantly suppressing MDSCs and 
Treg cells in vivo.98,99,102 Alternative TKIs, such as sorafenib 
(which currently serves as a second-line therapy for RCC), 
may not be as preferred as a vaccine or cotherapeutic agent, 
given its reported inhibitory effects on DCs and T cells.103 
An additional immunotherapeutic benefit of sunitinib and 
other antiangiogenic drugs, is predicated on their ability to 
“normalize” the tumor vasculature, leading to a decrease 
in interstitial fluid pressure and improved  delivery of 
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 chemotherapeutic drugs and effector T cells into the TME.104 
However, enhanced T-cell infiltration into the TME is not a 
passive event. Our group has recently shown that sunitinib 
activates tumor VEC expression of VCAM-1 and Mig 
(CXCL9), which serve to recruit (CXCR3+) type-1 tumor 
infiltrating lymphocyte (TIL) (unpublished data). In theory, 
sunitinib cotherapy may condition the TME for improved 
recruitment and sustained function of RCC vaccine-induced 
T effector cells,105 thereby prolonging the dramatic early OCR 
characteristic of sunitinib.
Summary and additional 
considerations
Early clinical results published over a decade ago showed that 
IFN-α
2a
− and IL-2-based immunotherapy provided survival 
advantage to patients compared with control groups.106,107 
However, a recent study has called these earlier findings into 
question by demonstrating that there may be little survival 
benefit from either of these cytokines when applied alone or 
in combination, and that they may induce a significant risk 
of toxicity.108 IL-2 is known to promote Treg cell responses 
in vitro and in vivo.109 As such, its less-than-ideal activity 
might have been predicted, given its ability to potentiate 
aspects of the dysfunctional or inappropriate polarization by 
the adaptive immune system in the majority of patients with 
tumors.78,110 Given the information, we have collated and pro-
posed that a successful combinational therapeutic platform 
must include the integration of appropriate immunogeneic 
tumor antigens in order to focus immunity toward carci-
noma cells with adjuvants that activate and “license” APCs 
to preferentially prime or activate type-1 antitumor T cells 
plus additional stimuli that may 1) support vaccine-activated 
T-cell survival, resistance to tumor-induced immune deviation 
and conversion to memory status; 2) prevent or remove the 
opposing influence of existing immune suppression (tumor, 
MDSC, Treg); 3) normalize the TME, thereby allowing for 
improved delivery of vaccine-induced T effector cells (and 
type-1 APCs) into the TME; and 4) promote reiterative 
rounds of T-cell cross-priming in the tumor draining lymph 
nodes leading to an expansion in the functional antitumor 
T-cell repertoire via a process akin to “epitope spreading” 
(a classical autoimmune paradigm). In such optimized 
protocols, one would expect a minor cohort of patients to 
exhibit a complete response (based on RECIST criteria), but 
perhaps of equal importance, a sizeable cohort of patients 
develop stabilization of their disease or tumor dormancy. If 
vaccines are successful in attaining even a transient state of 
dominance for type-1 antitumor immunity, one would predict 
the consequential development of compensatory regulatory 
immunity to limit this “autoimmunity”, allowing for the 
resumed growth of micro- or macroscopic metastases. Given 
such concerns, and despite their potential to unveil untoward 
autoimmune pathology, maintenance booster vaccines will 
likely be mandated to significantly prolong median time to 
progression and overall survival.
Notably, it has recently also become possible to consider 
the immune targeting of the tumor vasculature based on 
vaccines formulated using antigens that are differentially 
expressed by either VECs (ie, EphA2)111 or pericytes 
(ie, PDGFRβ112 or NG2113). In such cases, specific T cells may 
destroy or dysregulate tumor angiogenesis in a prolonged 
fashion (based on T-cell memory) and in a manner that is 
independent of other therapeutics, such as TKIs, which may 
put selective pressure on tumor cells. Furthermore, focusing 
type-1 T-cell responses on tumor-associated vascular cells 
may foster corollary recruitment (based on CXCR3 ligand 
chemokine production and endothelial cell expression of 
VCAM-1) of type-1 T cells that have been cross-primed 
against additional RCCAAs.
We have come far in the past decade in developing a 
better understanding of how the immune system recognizes 
RCC and how the optimal function of protective anti-RCC 
T-cell-mediated immunity may be altered in chronic dis-
ease states. Only now, we are becoming skilled at applying 
agents in the appropriate combinations, quantities, and 
schedules to allow for the normalization and maintenance 
of protective immunity. By adopting a stepwise progression 
through randomized prospective trials integrating sensitive 
and appropriate immunomonitoring methodologies, we will 
soon develop a consensus regarding optimal (combinational) 
vaccine-based immunotherapy approaches for the treatment 
of RCC. Upon consideration of the frustration in treating 
metastatic RCC and the distress of such patients, combina-
tional protocols that integrate anti-RCCAA vaccines and 
angiogenic inhibitors promoting tumor apoptosis should be 
prioritized in the immediate future, as such strategies may 
greatly improve the outcome of patients with advanced-
stage disease.
Acknowledgments
This work was supported by the National Institutes of 
Health (NIH) grants R01 CA114071 and P01 CA109688 
(to WJS).
Disclosure
The authors report no conflicts of interest in this work.
Open Access Journal of Urology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
135
Update on RCC vaccines
References
 1. Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M. 
Immunotherapy in metastatic renal cell carcinoma. World J Urol. 2005; 
23(3):196–201.
 2. Finke JH, Tubbs R, Connelly B, Pontes E, Montie J. Tumor-infiltrating 
lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci. 
1988;532:387–394.
 3. Finke JH, Rayman P, Edinger M, et al. Characterization of a human 
renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother. 
1992;11(1):1–11.
 4. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of spe-
cific cytolytic immune responses against autologous tumor in humans 
bearing malignant melanoma. J Immunol. 1987;138(3):989–995.
 5. Schendel DJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis 
of human renal cell carcinomas by tumor-infiltrating lymphocytes. 
I. HLA-A2-restricted recognition of autologous and allogeneic tumor 
lines. J Immunol. 1993;151(8):4209–4220.
 6. Ritchie AW, deKernion JB. The natural history and clinical features of 
renal carcinoma. Semin Nephrol. 1987;7(2):131–139.
 7. Lokich J. Spontaneous regression of metastatic renal cancer. Case report 
and literature review. Am J Clin Oncol. 1997;20(4):416–418.
 8. Penn I. Primary kidney tumors before and after renal transplantation. 
Transplantation. 1995;59(4):480–485.
 9. Kolbeck PC, Kaveggia FF, Johansson SL, Grune MT, Taylor RJ. The 
relationships among tumor-infiltrating lymphocytes, histopathologic 
findings, and long-term clinical follow-up in renal cell carcinoma. 
Mod Pathol. 1992;5(4):420–425.
 10. Hernberg M. Lymphocyte subsets as prognostic markers for can-
cer patients receiving immunomodulative therapy. Med Oncol. 
1999;16(3):145–153.
 11. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral 
CD8(+) T-lymphocytes as a prognostic factor in human renal cell 
carcinoma: clinicopathologic demonstration of antitumor immunity. 
Cancer Res. 2001;61(13):5132–5136.
 12. Kondo T, Nakazawa H, Ito F, et al. Favorable prognosis of renal cell 
carcinoma with increased expression of chemokines associated with a 
Th1-type immune response. Cancer Sci. 2006;97(8):780–786.
 13. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal 
recruitment and activation of dendritic cells within renal cell carcinoma. 
Clin Cancer Res. 1998;4(3):585–593.
 14. Uzzo RG, Rayman P, Kolenko V, et al. Mechanisms of apoptosis in 
T cells from patients with renal cell carcinoma. Clin Cancer Res. 
1999;5(5):1219–1229.
 15. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered 
maturation and early apoptosis of monocyte-derived dendritic cells. 
J Immunol. 2000;164(3):1269–1276.
 16. Rayman P, Wesa AK, Richmond AL, et al. Effect of renal cell carcino-
mas on the development of type 1 T-cell responses. Clin Cancer Res. 
2004;10(18 Pt 2):6360S–6366S.
 17. Tatsumi T, Herrem CJ, Olson WC, et al. Disease stage varia-
tion in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine 
kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 
2003;63(15):4481–4489.
 18. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in 
T helper type 1 (Th1)/Th2 CD4+ T cell responses against MAGE-6 in 
HLA-DRB1*0401+ patients with renal cell carcinoma or melanoma. 
J Exp Med. 2002;196(5):619–628.
 19. Onishi T, Ohishi Y, Imagawa K, Ohmoto Y, Murata K. An assessment of 
the immunological environment based on intratumoral cytokine produc-
tion in renal cell carcinoma. BJU Int. 1999;83(4):488–492.
 20. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells 
in renal cell carcinoma patients and investigation of correlation with 
survival. Cancer Immunol Immunother. 2007;56(11): 1743–1753.
 21. Saff RR, Spanjaard ES, Hohlbaum AM, Marshak-Rothstein A. 
Activation-induced cell death limits effector function of CD4 tumor-
specific T cells. J Immunol. 2004;172(11):6598–6606.
 22. Lu B, Finn OJ. T-cell death and cancer immune tolerance. Cell Death 
Differ. 2008;15(1):70–79.
 23. Giermasz AS, Urban JA, Nakamura Y, et al. Type-1 polarized dendritic 
cells primed for high IL-12 production show enhanced activity as cancer 
vaccines. Cancer Immunol Immunother. 2009;58(8):1329–1336.
 24. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell 
polarization. Nat Rev Immunol. 2003;3(12):984–993.
 25. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008; 
29(3):372–383.
 26. Radhakrishnan S, Wiehagen KR, Pulko V, et al. Induction of a Th1 
response from Th2-polarized T cells by activated dendritic cells: depen-
dence on TCR: peptide-MHC interaction, ICAM-1, IL-12, and IFN-γ1. 
J Immunol. 2007;178(6):3583–3592.
 27. Krawczyk CM, Shen H, Pearce EJ. Functional plasticity in memory T 
helper cell responses. J Immunol. 2007;178(7):4080–4088.
 28. Arroyo JC, Gabilondo F, Llorente L, Meraz-Rios MA, Sanchez-
Torres C. Immune response induced in vitro by CD16− and CD16+ 
monocyte-derived dendritic cells in patients with metastatic renal cell 
carcinoma treated with dendritic cell vaccines. J Clin Immunol. 2004; 
24(1):86–96.
 29. Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. Polarized 
type-1 dendritic cells (DC1) producing high levels of IL-12 family 
members rescue patient TH1-type antimelanoma CD4+ T cell responses 
in vitro. J Immunother. 2007;30(1):75–82.
 30. Lipscomb MW, Chen L, Taylor JL, et al. Ectopic T-bet expression 
licenses dendritic cells for IL-12-independent priming of type 1 T cells 
in vitro. J Immunol. 2009;183(11):7250–7258.
 31. Uemura H, Fujimoto K, Tanaka M, et al. A phase I trial of vaccination of 
CA9-derived peptides for HLA-A24+ patients with cytokine-refractory met-
astatic renal cell carcinoma. Clin Cancer Res. 2006;12(6):1768–1775.
 32. Iiyama T, Udaka K, Takeda S, et al. WT1 (Wilms’ tumor 1) pep-
tide immunotherapy for renal cell carcinoma. Microbiol Immunol. 
2007;51(5):519–530.
 33. Rahma OE, Ashtar E, Ibrahim R, et al. A pilot clinical trial testing mutant 
von Hippel-Lindau peptide as a novel immune therapy in metastatic 
renal cell carcinoma. J Transl Med. 8:8.
 34. Miller GA, Pontes JE, Huben RP, Goldrosen MH. Humoral immune 
response of patients receiving specific active immunotherapy for renal 
cell carcinoma. Cancer Res. 1985;45(9):4478–4482.
 35. Tani K, Nakazaki Y, Hase H, et al. Progress reports on immune gene 
therapy for stage IV renal cell cancer using lethally irradiated granulo-
cyte-macrophage colony-stimulating factor-transduced autologous renal 
cancer cells. Cancer Chemother Pharmacol. 2000;46 Suppl:S73–S76.
 36. Maini A, Nishisaka N, Kinoshita Y, Jones RF, Wang CY, Haas GP. 
Combination of radiation and vaccination with autologous tumor cells 
expressing IL-2, IFN-gamma and GM-CSF for treatment of murine 
renal carcinoma. In vivo. 2003;17(2):119–123.
 37. Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination 
with electrofused allogeneic dendritic cells/autologous tumor-derived 
cells in patients with stage IV renal cell carcinoma. J Immunother. 
2007;30(7):749–761.
 38. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, 
Vieweg J. Human dendritic cells transfected with renal tumor RNA 
stimulate polyclonal T-cell responses against antigens expressed by 
primary and metastatic tumors. Cancer Res. 2001;61(8):3388–3393.
 39. Geiger C, Regn S, Weinzierl A, Noessner E, Schendel DJ. A generic 
RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. 
J Transl Med. 2005;3:29.
 40. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in 
metastatic renal cancer patients vaccinated with tumor RNA-transfected 
dendritic cells. Cancer Res. 2003;63(9):2127–2133.
 41. Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical 
responses after vaccinations with peptide-pulsed dendritic cells in met-
astatic renal cancer patients. Cancer Res. 2006;66(11): 5910–5918.
 42. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al. Preliminary  analysis 
of patients with progressive renal cell carcinoma vaccinated with CA9-
peptide-pulsed mature dendritic cells. J Immunother. 2007;30(1):116–122.
Open Access Journal of Urology 2010:2submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
136
Chi et al
 43. Zamparese R, Pannone G, Santoro A, et al. Survivin expression in renal 
cell carcinoma. Cancer Invest. 2008;26(9):929–935.
 44. Alves PM, Faure O, Graff-Dubois S, et al. EphA2 as target of anticancer 
immunotherapy: identification of HLA-A*0201-restricted epitopes. 
Cancer Res. 2003;63(23):8476–8480.
 45. Scardino A, Alves P, Gross DA, et al. Identification of HER-2/neu 
immunogenic epitopes presented by renal cell carcinoma and other 
human epithelial tumors. Eur J Immunol. 2001;31(11):3261–3270.
 46. Aubert S, Fauquette V, Hemon B, et al. MUC1, a new hypoxia induc-
ible factor target gene, is an actor in clear renal cell carcinoma tumor 
progression. Cancer Res. 2009;69(14):5707–5715.
 47. Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carci-
noma-associated antigen G250 encodes a human leukocyte antigen 
(HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. 
Cancer Res. 1999;59(21):5554–5559.
 48. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. 
Immunohistological distribution of 5T4 antigen in normal and malignant 
tissues. Br J Cancer. 1990;61(1):89–95.
 49. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expres-
sion of tumor-associated carbonic anhydrases. Cancer Res. 2000; 
60(24):7075–7083.
 50. Ashida S, Nishimori I, Tanimura M, Onishi S, Shuin T. Effects of von 
Hippel-Lindau gene mutation and methylation status on expression of 
transmembrane carbonic anhydrases in renal cell carcinoma. J Cancer 
Res Clin Oncol. 2002;128(10):561–568.
 51. Shimizu K, Uemura H, Yoshikawa M, et al. Induction of antigen specific 
cellular immunity by vaccination with peptides from MN/CA IX in 
renal cell carcinoma. Oncol Rep. 2003;10(5):1307–1311.
 52. Shvarts O, Janzen N, Lam JS, et al. RENCA/carbonic anhydrase-IX: a 
murine model of a carbonic anhydrase-IX-expressing renal cell carci-
noma. Urology. 2006;68(5):1132–1138.
 53. Bauer S, Oosterwijk-Wakka JC, Adrian N, et al. Targeted therapy of 
renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. 
Int J Cancer. 2009;125(1):115–123.
 54. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 
oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-
based immunotherapy. Br J Cancer. 2005;93(6):670–677.
 55. Shaw DM, Connolly NB, Patel PM, et al. A phase II study of a 5T4 
oncofoetal antigen tumour-targeted superantigen (ABR-214936) 
therapy in patients with advanced renal cell carcinoma. Br J Cancer. 
2007;96(4):567–574.
 56. Amato RJ, Shingler W, Naylor S, et al. Vaccination of renal cell cancer 
patients with modified vaccinia ankara delivering tumor antigen 5T4 
(TroVax) administered with interleukin 2: a phase II trial. Clin Cancer 
Res. 2008;14(22):7504–7510.
 57. Kaufman HL, Taback B, Sherman W, et al. Phase II trial of Modified Vac-
cinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) 
in patients with metastatic renal cell carcinoma. J Transl Med. 2009;7:2.
 58. Hawkins RE, Macdermott C, Shablak A, et al. Vaccination of patients 
with metastatic renal cancer with modified vaccinia Ankara encoding 
the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. 
J Immunother. 2009;32(4):424–429.
 59. Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell 
cancer patients with modified vaccinia Ankara delivering the tumor antigen 
5T4 (TroVax) alone or administered in combination with interferon-alpha 
(IFN-alpha): a phase 2 trial. J Immunother. 2009;32(7):765–772.
 60. Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus 
MART-1-engineered autologous dendritic cell vaccine for metastatic 
melanoma. J Immunother. 2008;31(3):294–309.
 61. Carmichael MG, Benavides LC, Holmes JP, et al. Results of the first 
phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-
free breast cancer patients: United States Military Cancer Institute 
Clinical Trials Group Study I-04. Cancer. 2010;116(2):292–301.
 62. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and 
clinical outcomes of vaccination with a multiepitope melanoma peptide 
vaccine plus low-dose interleukin-2 administered either concurrently 
or on a delayed schedule. J Clin Oncol. 2004;22(22):4474–4485.
 63. Suekane S, Nishitani M, Noguchi M, et al. Phase I trial of  personalized 
peptide vaccination for cytokine-refractory metastatic renal cell carci-
noma patients. Cancer Sci. 2007;98(12):1965–1968.
 64. Dakappagari NK, Sundaram R, Rawale S, Liner A, Galloway DR, 
Kaumaya PT. Intracellular delivery of a novel multiepitope  peptide 
vaccine by an amphipathic peptide carrier enhances cytotoxic 
T-cell responses in HLA-A*0201 mice. J Pept Res. 2005;65(2): 
189–199.
 65. Uemura H, De Velasco MA. Tumor vaccines in renal cell carcinoma. 
World J Urol. 2008;26(2):147–154.
 66. Asemissen AM, Brossart P. Vaccination strategies in patients with 
renal cell carcinoma. Cancer Immunol Immunother. 2009;58(7): 
1169–1174.
 67. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response 
to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 
2008;8:1.
 68. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond 
current paradigms. Clin Cancer Res. 2007;13(13):3776–3782.
 69. Zhou J, Weng D, Zhou F, et al. Patient-derived renal cell carcinoma 
cells fused with allogeneic dendritic cells elicit anti-tumor activity: in 
vitro results and clinical responses. Cancer Immunol Immunother. 2009; 
58(10):1587–1597.
 70. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal 
tumour cell vaccine and risk of tumour progression in patients with 
renal-cell carcinoma after radical nephrectomy: phase III, randomised 
controlled trial. Lancet. 2004;363(9409):594–599.
 71. Berntsen A, Trepiakas R, Wenandy L, et al. Therapeutic dendritic cell 
vaccination of patients with metastatic renal cell carcinoma: a clinical 
phase 1/2 trial. J Immunother. 2008;31(8):771–780.
 72. Schwaab T, Schwarzer A, Wolf B, et al. Clinical and immunologic 
effects of intranodal autologous tumor lysate-dendritic cell vaccine 
with Aldesleukin (Interleukin 2) and IFN-{alpha}
2a
 therapy in meta-
static renal cell carcinoma patients. Clin Cancer Res. 2009;15(15): 
4986–4992.
 73. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer 
vaccine therapy: results of a workshop sponsored by the Society for 
Biological Therapy. J Immunother. 2002;25(2):97–138.
 74. Lyerly HK. Quantitating cellular immune responses to cancer vaccines. 
Semin Oncol. 2003;30(3 Suppl 8):9–16.
 75. Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U. Immuno-
logical monitoring of cancer vaccine therapy. Expert Opin Biol Ther. 
2004;4(10):1677–1684.
 76. Antonia SJ, Seigne J, Diaz J, et al. Phase I trial of a B7-1 (CD80) gene 
modified autologous tumor cell vaccine in combination with systemic 
interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 
2002;167(5):1995–2000.
 77. Feldman ED, Weinreich DM, Carroll NM, et al. Interferon gamma-
inducible protein 10 selectively inhibits proliferation and induces 
apoptosis in endothelial cells. Ann Surg Oncol. 2006;13(1):125–133.
 78. Lemoine FM, Cherai M, Giverne C, et al. Massive expansion of 
regulatory T-cells following interleukin 2 treatment during a phase I-II 
dendritic cell-based immunotherapy of metastatic renal cancer. Int J 
Oncol. 2009;35(3):569–581.
 79. Lamers CH, Langeveld SC, Groot-van Ruijven CM, Debets R, Sleijfer S, 
Gratama JW. Gene-modified T cells for adoptive immunotherapy of 
renal cell cancer maintain transgene-specific immune functions in vivo. 
Cancer Immunol Immunother. 2007;56(12):1875–1883.
 80. Fenton RG, Steis RG, Madara K, et al. A phase I randomized study of 
subcutaneous adjuvant IL-2 in combination with an autologous tumor 
vaccine in patients with advanced renal cell carcinoma. J Immunother 
Emphasis Tumor Immunol. 1996;19(5):364–374.
 81. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of 
CD4+CD25+ regulatory T cells in patients treated with high-dose 
interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin 
Oncol. 2006;24(7):1169–1177.
 82. Anton P, Kirchner H, Jonas U, Atzpodien J. Cytokines and tumor 
 vaccination. Cancer Biother Radiopharm. 1996;11(5):315–318.
Open Access Journal of Urology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
137
Update on RCC vaccines
 83. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous 
irradiated renal cell carcinoma vaccines generated by ex vivo gran-
ulocyte-macrophage colony-stimulating factor gene transfer. Cancer 
Res. 1997;57(8):1537–1546.
 84. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated 
antitumor immunity in cancer patients after depletion of regulatory 
T cells. J Clin Invest. 2005;115(12):3623–3633.
 85. Holtl L, Ramoner R, Zelle-Rieser C, et al. Allogeneic dendritic cell 
vaccination against metastatic renal cell carcinoma with or without 
cyclophosphamide. Cancer Immunol Immunother. 2005;54(7): 
663–670.
 86. web.ncifcrf.gov/research/brb/workshops/NCI. National Institute of 
Health; NCI Immunotherapy Agent Workshop Proceedings; 2007. 
Available from: http://web.ncifcrf.gov/research/brb/workshops/
NCI.
 87. Yang JC, Beck KE, Blansfield JA, et al. Tumor regression in patients 
with metastatic renal cancer treated with a monoclonal antibody to 
CTLA4 (MDX-010) [abstract]. J Clin Oncol (ASCO Annual Meetings 
Proceedings). 2005;23(16s, pt I of II, June 1 Suppl):2501.
 88. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-
associated antigen-4 blockage can induce autoimmune hypophysitis 
in patients with metastatic melanoma and renal cancer. J Immunother. 
2005;28(6):593–598.
 89. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 anti-
body therapy associated autoimmune hypophysitis: serious immune 
related adverse events across a spectrum of cancer subtypes. Pituitary. 
2010;13(1):29–38.
 90. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves 
differentiation of myeloid cells and immune response in cancer 
patients. Cancer Res. 2006;66(18):9299–9307.
 91. Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cell-mediated 
immunosuppression in patients with metastatic renal cell carcinoma. 
Clin Cancer Res. 2008;14(24):8270–8278.
 92. Furugaki K, Pokorna K, Le Pogam C, et al. DNA vaccination with 
all-trans retinoic acid treatment induces long-term survival and 
elicits specific immune responses requiring CD4+ and CD8+ T-cell 
activation in an acute promyelocytic leukemia mouse model. Blood. 
2010;115(3):653–656.
 93. Schambach F, Schupp M, Lazar MA, Reiner SL. Activation of retinoic 
acid receptor-alpha favours regulatory T cell induction at the expense 
of IL-17-secreting T helper cell differentiation. Eur J Immunol. 
2007;37(9):2396–2399.
 94. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and 
updated results for sunitinib compared with interferon alfa in 
patients with metastatic renal cell carcinoma. [abstract] J Clin Oncol. 
2009;27(22):3584–3590.
 95. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib 
for metastatic renal-cell carcinoma: an expanded-access trial. Lancet 
Oncol. 2009;10(8):757–763.
 96. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib 
administered in a continuous once-daily dosing regimen in patients 
with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 
2009;27(25):4068–4075.
 97. van Cruijsen H, van der Veldt AA, Vroling L, et al. Sunitinib-induced 
myeloid lineage redistribution in renal cell cancer patients: CD1c+ 
dendritic cell frequency predicts progression-free survival. Clin Cancer 
Res. 2008;14(18):5884–5892.
 98. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune 
suppression and decreases T-regulatory cells in renal cell carcinoma 
patients. Clin Cancer Res. 2008;14(20):6674–6682.
 99. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-
derived suppressor cell accumulation in renal cell carcinoma patients. 
Clin Cancer Res. 2009;15(6):2148–2157.
 100. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase 
inhibitor in the reversal of immune suppression and modulation of 
tumor microenvironment for immune-based cancer therapies. Cancer 
Res. 2009;69(6):2514–2522.
 101. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition 
of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces 
immunosuppressive cells. Cancer Res. 2009;69(6):2506–2513.
 102. Abe F, Younos I, Westphal S, et al. Therapeutic activity of sunitinib 
for Her2/neu induced mammary cancer in FVB mice. Int Immunop-
harmacol. 2010;10(1):140–145.
 103. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects 
function of dendritic cells and induction of primary immune responses. 
Blood. 2008;111(12):5610–5620.
 104. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by 
sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 
2008;14(5):1540–1549.
 105. Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer – 
when TKIs are not enough. Nat Rev Clin Oncol. 2009;6(8):478–487.
 106. Flessner MF, Dedrick RL. Tissue-level transport mechanisms of 
intraperitoneally-administered monoclonal antibodies. J Control 
Release. 1998;53(1–3):69–75.
 107. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective random-
ized trial of interferon alfa-2a plus vinblastine versus vinblastine 
alone in patients with advanced renal cell cancer. J Clin Oncol. 
1999;17(9):2859–2867.
 108. Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon 
alfa-2a, interleukin 2, or combination of both cytokines in patients 
with metastatic renal carcinoma of intermediate prognosis: results of 
a randomized controlled trial. Cancer. 2007;110(11):2468–2477.
 109. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 
therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 
2005;11(11):1238–1243.
 110. Jensen HK, Donskov F, Nordsmark M, Marcussen N, von der 
Maase H. Increased intratumoral FOXP3-positive regulatory immune 
cells during interleukin-2 treatment in metastatic renal cell carcinoma. 
Clin Cancer Res. 2009;15(3):1052–1058.
 111. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. 
The ephrin-A1 ligand and its receptor, EphA2, are expressed during 
tumor neovascularization. Oncogene. 2000;19(52):6043–6052.
 112. Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonen-
dothelial sources of PDGF-B regulate pericyte recruitment and 
influence vascular pattern formation in tumors. J Clin Invest. 
2003;112(8):1142–1151.
 113. Ozerdem U, Monosov E, Stallcup WB. NG2 proteoglycan expres-
sion by pericytes in pathological microvasculature. Microvasc Res. 
2002;63(1):129–134.
 114. Reker S, Meier A, Holten-Andersen L, et al. Identification of novel sur-
vivin-derived CTL epitopes. Cancer Biol Ther. 2004;3(2):173–179.
 115. Siegel S, Wagner A, Friedrichs B, et al. Identification of HLA-A*0201-
presented T cell epitopes derived from the oncofetal antigen-immature 
laminin receptor protein in patients with hematological malignancies. 
J Immunol. 2006;176(11):6935–6944.
 116. Zelle-Rieser C, Barsoum AL, Sallusto F, et al. Expression and immu-
nogenicity of oncofetal antigen-immature laminin receptor in human 
renal cell carcinoma. J Urol. 2001;165(5):1705–1709.
 117. Dengjel J, Nastke MD, Gouttefangeas C, et al. Unexpected abundance 
of HLA class II presented peptides in primary renal cell carcinomas. 
Clin Cancer Res. 2006;12(14 Pt 1):4163–4170.
 118. Takahashi M, Papavero V, Yuhas J, et al. Altered expression of mem-
bers of the IGF-axis in clear cell renal cell carcinoma. Int J Oncol. 
2005;26(4):923–931.
 119. Herrem CJ, Tatsumi T, Olson KS, et al. Expression of EphA2 is prognostic 
of disease-free interval and overall survival in surgically treated patients 
with renal cell carcinoma. Clin Cancer Res. 2005;11(1):226–231.
 120. Van Den Eynde BJ, Gaugler B, Probst-Kepper M, et al. A new 
antigen recognized by cytolytic T lymphocytes on a human kid-
ney tumor results from reverse strand transcription. J Exp Med. 
1999;190(12):1793–1800.
 121. Shomura H, Shichijo S, Matsueda S, et al. Identification of epidermal 
growth factor receptor-derived peptides immunogenic for HLA-A2(+) 
cancer patients. Br J Cancer. 2004;90(8):1563–1571.
Open Access Journal of Urology 2010:2submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
138
Chi et al
 122. Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A. 
Epidermal growth factor receptor gene expression in normal human 
kidney and renal cell carcinoma. J Urol. 1989;142(5):1364–1368.
 123. Sato E, Torigoe T, Hirohashi Y, et al. Identification of an immunogenic 
CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. 
Clin Cancer Res. 2008;14(21):6916–6923.
 124. Schag K, Schmidt SM, Muller MR, et al. Identif ication of 
C-met oncogene as a broadly expressed tumor-associated anti-
gen recognized by cytotoxic T-lymphocytes. Clin Cancer Res. 
2004;10(11):3658–3666.
 125. Campbell CE, Kuriyan NP, Rackley RR, et al. Constitutive expression 
of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma. 
Int J Cancer. 1998;78(2):182–188.
 126. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy target-
ing Wilms’ tumor gene WT1 product. J Immunol. 2000;164(4): 
1873–1880.
 127. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leu-
kemic CD34+ progenitor cells by cytotoxic T lymphocytes specific 
for WT1. Blood. 2000;95(7):2198–2203.
 128. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of 
leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for 
WT1 peptide. Blood. 2000;95(1):286–293.
 129. Muller MR, Grunebach F, Nencioni A, Brossart P. Transfection of den-
dritic cells with RNA induces CD4- and CD8-mediated T cell immu-
nity against breast carcinomas and reveals the immunodominance of 
presented T cell epitopes. J Immunol. 2003;170(12):5892–5896.
 130. Hiltbold EM, Ciborowski P, Finn OJ. Naturally processed class II 
epitope from the tumor antigen MUC1 primes human CD4+ T cells. 
Cancer Res. 1998;58(22):5066–5070.
 131. Redchenko I, Harrop R, Ryan MG, Hawkins RE, Carroll MW. Iden-
tification of a major histocompatibility complex class I-restricted 
T-cell epitope in the tumour-associated antigen, 5T4. Immunology. 
2006;118(1):50–57.
 132. Elkord E, Burt DJ, Drijfhout JW, Hawkins RE, Stern PL. CD4+ 
T-cell recognition of human 5T4 oncofoetal antigen: implications 
for initial depletion of CD25+ T cells. Cancer Immunol Immunother. 
2008;57(6):833–847.
 133. Smyth LJ, Elkord E, Taher TE, et al. CD8 T-cell recognition of human 
5T4 oncofetal antigen. Int J Cancer. 2006;119(7):1638–1647.
 134. Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, 
Triebel F. A non-AUG-defined alternative open reading frame of the 
intestinal carboxyl esterase mRNA generates an epitope recognized 
by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in 
situ. J Immunol. 1999;163(1):483–490.
 135. Yokoyama Y, Grunebach F, Schmidt SM, et al. Matrilysin (MMP-7) 
is a novel broadly expressed tumor antigen recognized by antigen-
specific T cells. Clin Cancer Res. 2008;14(17):5503–5511.
 136. Sumi T, Nakatani T, Yoshida H, et al. Expression of matrix metallo-
proteinases 7 and 2 in human renal cell carcinoma. Oncol Rep. 2003; 
10(3):567–570.
 137. Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G. Cyclin-D1 
expression in human renal-cell carcinoma. Int J Cancer. 1999; 
84(3):268–272.
 138. Kondo E, Maecker B, Weihrauch MR, et al. Cyclin D1-specific cyto-
toxic T lymphocytes are present in the repertoire of cancer patients: 
implications for cancer immunotherapy. Clin Cancer Res. 2008; 
14(20):6574–6579.
 139. Mathieu MG, Linley AJ, Reeder SP, et al. HAGE, a cancer/testis 
antigen expressed at the protein level in a variety of cancers. Cancer 
Immun.10:2.
 140. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase 
catalytic subunit is a widely expressed tumor-associated antigen recog-
nized by cytotoxic T lymphocytes. Immunity. 1999;10(6):673–679.
 141. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, 
Zanetti M. Cytotoxic T cell immunity against telomerase reverse 
transcriptase in humans. Proc Natl Acad Sci U S A. 2000;97(9): 
4796–4801.
 142. Schroers R, Shen L, Rollins L, et al. Human telomerase reverse 
transcriptase-specific T-helper responses induced by promiscuous 
major histocompatibility complex class II-restricted epitopes. Clin 
Cancer Res. 2003;9(13):4743–4755.
 143. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal 
cancer antigen through post-translational protein splicing. Nature. 
2004;427(6971):252–256.
 144. Young AC, Craven RA, Cohen D, et al. Analysis of VHL gene alterations 
and their relationship to clinical parameters in sporadic conventional 
renal cell carcinoma. Clin Cancer Res. 2009;15(24):7582–7592.
 145. Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. 
Expression of MAGE genes in renal cell carcinoma. Int J Mol Med. 
1998;2(1):57–60.
 146. Kawagoe N, Shintaku I, Yutani S, et al. Expression of the 
SART3 tumor rejection antigen in renal cell carcinoma. J Urol. 
2000;164(6):2090–2095.
 147. Mohamed ER, Naito M, Terasaki Y, et al. Capability of SART3 
(109–118) peptide to induce cytotoxic T lymphocytes from prostate 
cancer patients with HLA class I-A11, -A31 and -A33 alleles. Int J 
Oncol. 2009;34(2):529–536.
 148. Minami T, Matsueda S, Takedatsu H, et al. Identification of SART3-
 derived peptides having the potential to induce cancer-reactive cytotoxic 
T lymphocytes from prostate cancer patients with HLA-A3 supertype 
alleles. Cancer Immunol Immunother. 2007;56(5):689–698.
 149. Ito M, Shichijo S, Miyagi Y, et al. Identification of SART3-derived 
peptides capable of inducing HLA-A2-restricted and tumor-specific 
CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer. 
2000;88(4):633–639.
 150. Nakao M, Shichijo S, Imaizumi T, et al. Identification of a gene coding 
for a new squamous cell carcinoma antigen recognized by the CTL. 
J Immunol. 2000;164(5):2565–2574.
 151. Neumann E, Engelsberg A, Decker J, et al. Heterogeneous expression 
of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 
75 in human renal cell carcinoma: candidates for T-cell-based immu-
notherapies? Cancer Res. 1998;58(18):4090–4095.
 152. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identifica-
tion of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes 
in the widely expressed tumor antigen PRAME by proteasome-
mediated digestion analysis. J Exp Med. 2001;193(1):73–88.
 153. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that 
is recognized on a melanoma showing partial HLA loss by CTL express-
ing an NK inhibitory receptor. Immunity. 1997;6(2):199–208.
 154. Kawahara M, Hori T, Matsubara Y, Okawa K, Uchiyama T. Identi-
fication of HLA class I-restricted tumor-associated antigens in adult 
T cell leukemia cells by mass spectrometric analysis. Exp Hematol. 
2006;34(11):1496–1504.
 155. Kankuri M, Soderstrom KO, Pelliniemi TT, Vahlberg T, Pyrhonen S, 
Salminen E. The association of immunoreactive p53 and Ki-67 with 
T-stage, grade, occurrence of metastases and survival in renal cell 
carcinoma. Anticancer Res. 2006;26(5B):3825–3833.
 156. Chikamatsu K, Nakano K, Storkus WJ, et al. Generation of anti-p53 
cytotoxic T lymphocytes from human peripheral blood using autolo-
gous dendritic cells. Clin Cancer Res. 1999;5(6):1281–1288.
 157. Oehlrich N, Devitt G, Linnebacher M, et al. Generation of RAGE-1 
and MAGE-9 peptide-specif ic cytotoxic T-lymphocyte lines 
for transfer in patients with renal cell carcinoma. Int J Cancer. 
2005;117(2):256–264.
 158. Tatsumi T, Kierstead LS, Ranieri E, et al. MAGE-6 encodes HLA-
DRβ1*0401-presented epitopes recognized by CD4+ T cells from 
patients with melanoma or renal cell carcinoma. Clin Cancer Res. 
2003;9(3):947–954.
 159. Kramer BF, Schoor O, Kruger T, et al. MAGED4-expression in renal cell 
carcinoma and identification of an HLA-A*25-restricted MHC class I 
ligand from solid tumor tissue. Cancer Biol Ther. 2005;4(9):943–948.
 160. Sotiropoulou PA, Perez SA, Iliopoulou EG, et al. Cytotoxic T-cell 
precursor frequencies to HER-2
369–377
 in patients with HER-2/neu-
positive epithelial tumours. Br J Cancer. 2003;89(6):1055–1061.
Open Access Journal of Urology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
139
Update on RCC vaccines
 161. Sotiropoulou PA, Perez SA, Voelter V, et al. Natural CD8+ T-cell 
responses against MHC class I epitopes of the HER-2/neu oncopro-
tein in patients with epithelial tumors. Cancer Immunol Immunother. 
2003;52(12):771–779.
 162. Ishihara Y, Harada M, Azuma K, et al. HER2/neu-derived peptides 
recognized by both cellular and humoral immune systems in HLA-A2+ 
cancer patients. Int J Oncol. 2004;24(4):967–975.
 163. Rongcun Y, Salazar-Onfray F, Charo J, et al. Identification of new 
HER2/neu-derived peptide epitopes that can elicit specific CTL against 
autologous and allogeneic carcinomas and melanomas. J Immunol. 
1999;163(2):1037–1044.
 164. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promis-
cuous MHC class II helper T-cell epitopes for the HER2/neu tumor 
antigen. Cancer Res. 2000;60(18):5228–5236.
 165. Shintaku I, Kawagoe N, Yutani S, et al. Expression of the SART1 
tumor rejection antigen in renal cell carcinoma. Urol Res. 2000; 
28(3):178–184.
 166. Yamada A, Kawano K, Harashima N, et al. Study of HLA class I 
restriction and the directed antigens of cytotoxic T lymphocytes at the 
tumor sites of ovarian cancer. Cancer Immunol Immunother. 1999; 
48(2–3):147–152.
 167. Kikuchi M, Nakao M, Inoue Y, et al. Identification of a SART-1-derived 
peptide capable of inducing HLA-A24-restricted and tumor-specific 
cytotoxic T lymphocytes. Int J Cancer. 1999;81(3):459–466.
 168. Gaugler B, Brouwenstijn N, Vantomme V, et al. A new gene coding 
for an antigen recognized by autologous cytolytic T lymphocytes on 
a human renal carcinoma. Immunogenetics. 1996;44(5):323–330.
 169. Flad T, Spengler B, Kalbacher H, et al. Direct identification of major 
histocompatibility complex class I-bound tumor-associated peptide 
antigens of a renal carcinoma cell line by a novel mass spectrometric 
method. Cancer Res. 1998;58(24):5803–5811.
 170. Touloukian CE, Leitner WW, Robbins PF, et al. Expression of a 
“self-”antigen by human tumor cells enhances tumor antigen-specific 
CD4(+) T-cell function. Cancer Res. 2002;62(18):5144–5147.
 171. Slingluff CL Jr, Colella TA, Thompson L, et al. Melanomas with 
concordant loss of multiple melanocytic differentiation proteins: 
immune escape that may be overcome by targeting unique or undefined 
antigens. Cancer Immunol Immunother. 2000;48(12):661–672.
 172. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Iden-
tification of a gene encoding a melanoma tumor antigen recognized 
by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med. 
1995;181(2):799–804.
 173. Reckamp KL, Figlin RA, Moldawer N, et al. Expression of CXCR3 on 
mononuclear cells and CXCR3 ligands in patients with metastatic renal 
cell carcinoma in response to systemic IL-2 therapy. J Immunother. 
2007;30(4):417–424.
 174. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin 
Oncol. 2000;27(2):194–203.
 175. Tatsugami K, Eto M, Naito S. Influence of immunotherapy with 
interferon-alpha on regulatory T cells in renal cell carcinoma patients. 
J Interferon Cytokine Res. 2010;30(1):43–48.
 176. Unsinger J, McGlynn M, Kasten KR, et al. IL-7 promotes T cell 
viability, trafficking, and functionality and improves survival in sepsis. 
J Immunol. 2010;184(7):3768–3779.
 177. Andersson A, Yang SC, Huang M, et al. IL-7 promotes CXCR3 
ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol. 
2009;182(11):6951–6958.
 178. Bayer AL, Lee JY, de la Barrera A, Surh CD, Malek TR. A function 
for IL-7R for CD4+CD25+Foxp3+ T regulatory cells. J Immunol. 
2008;181(1):225–234.
 179. Ogawa M, Tsutsui T, Zou JP, et al. Enhanced induction of very late 
antigen 4/lymphocyte function-associated antigen 1-dependent T-cell 
migration to tumor sites following administration of interleukin 12. 
Cancer Res. 1997;57(11):2216–2222.
 180. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodi-
meric cytokines: new players in the regulation of T cell responses. 
Immunity. 2003;19(5):641–644.
 181. Indrova M, Bieblova J, Bubenik J, Reinis M. IL-12 immunotherapy 
of minimal residual disease in murine models of HPV16-associated 
tumours: induction of immune responses, cytokine production 
and kinetics of immune cell subsets. Int J Oncol. 2008;32(2): 
499–507.
 182. Basak GW, Zapala L, Wysocki PJ, Mackiewicz A, Jakobisiak M, 
Lasek W. Interleukin 15 augments antitumor activity of cytokine 
gene-modified melanoma cell vaccines in a murine model. Oncol Rep. 
2008;19(5):1173–1179.
 183. Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA. 
IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly 
govern CD4+Foxp3+ regulatory T cell development. J Immunol. 2008; 
181(5):3285–3290.
 184. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and 
interleukin-18 synergistically induce murine tumor regression 
which involves inhibition of angiogenesis. J Clin Invest. 1998; 
101(6):1441–1452.
 185. Robertson MJ, Kirkwood JM, Logan TF, et al. A dose-escalation 
study of recombinant human interleukin-18 using two different 
schedules of administration in patients with cancer. Clin Cancer Res. 
2008;14(11):3462–3469.
 186. Carroll RG, Carpenito C, Shan X, et al. Distinct effects of IL-18 on 
the engraftment and function of human effector CD8 T cells and 
regulatory T cells. PLoS One. 2008;3(9):e3289.
 187. Casey KA, Mescher MF. IL-21 promotes differentiation of 
naive CD8 T cells to a unique effector phenotype. J Immunol. 
2007;178(12):7640–7648.
 188. Ebert EC. Interleukin 21 up-regulates perforin-mediated cytotoxic 
activity of human intra-epithelial lymphocytes. Immunology. 
2009;127(2):206–215.
 189. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA. IL-21 
enhances and sustains CD8+ T cell responses to achieve durable 
tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. 
J Immunol. 2004;173(2):900–909.
 190. Wuest TY, Willette-Brown J, Durum SK, Hurwitz AA. The influence 
of IL-2 family cytokines on activation and function of naturally occur-
ring regulatory T cells. J Leukoc Biol. 2008;84(4):973–980.
 191. Cho HJ, Hayashi T, Datta SK, et al. IFN-alpha beta promote prim-
ing of antigen-specific CD8+ and CD4+ T lymphocytes by immu-
nostimulatory DNA-based vaccines. J Immunol. 2002;168(10): 
4907–4913.
 192. Sikora AG, Jaffarzad N, Hailemichael Y, et al. IFN-alpha enhances 
peptide vaccine-induced CD8+ T cell numbers, effector function, and 
antitumor activity. J Immunol. 2009;182(12):7398–7407.
 193. Mohty AM, Grob JJ, Mohty M, Richard MA, Olive D, Gaugler B. 
Induction of IP-10/CXCL10 secretion as an immunomodulatory effect 
of low-dose adjuvant interferon-alpha during treatment of melanoma. 
Immunobiology. 2010;215(2):113–123.
 194. Ogasawara K, Hida S, Weng Y, et al. Requirement of the IFN-alpha/
beta-induced CXCR3 chemokine signalling for CD8+ T cell activa-
tion. Genes Cells. 2002;7(3):309–320.
 195. Stewart TJ, Greeneltch KM, Reid JE, et al. Interferon regulatory 
factor-8 modulates the development of tumor-induced CD11b+Gr-1+ 
myeloid cells. J Cell Mol Med. 2009;13(9B):3939–3950.
 196. Kelchtermans H, De Klerck B, Mitera T, et al. Defective CD4+CD25+ 
regulatory T cell functioning in collagen-induced arthritis: an impor-
tant factor in pathogenesis, counter-regulated by endogenous IFN-
gamma. Arthritis Res Ther. 2005;7(2):R402–R415.
 197. Sercan O, Stoycheva D, Hammerling GJ, Arnold B, Schuler T. 
IFN-gamma receptor signaling regulates memory CD8+ T cell 
differentiation. J Immunol. 2010;184(6):2855–2862.
 198. Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-
colony-stimulating factor enhances immune responses to melanoma-
associated peptides in vivo. Int J Cancer. 1996;67(1):54–62.
 199. Kared H, Leforban B, Montandon R, et al. Role of GM-CSF in 
tolerance induction by mobilized hematopoietic progenitors. Blood. 
2008;112(6):2575–2578.
Open Access Journal of Urology 2010:2submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
140
Chi et al
 200. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. 
GM-CSF is one of the main breast tumor-derived soluble factors 
involved in the differentiation of CD11b-Gr1- bone marrow progeni-
tor cells into myeloid-derived suppressor cells. Breast Cancer Res 
Treat. 2009. [Epub ahead of print Nov 24].
 201. Tani K, Azuma M, Nakazaki Y, et al. Phase I study of autologous 
tumor vaccines transduced with the GM-CSF gene in four patients 
with stage IV renal cell cancer in Japan: clinical and immunological 
findings. Mol Ther. 2004;10(4):799–816.
 202. Na IK, Keilholz U, Letsch A, et al. Addition of GM-CSF to a 
peptide/KLH vaccine results in increased frequencies of CXCR3-
expressing KLH-specific T cells. Cancer Immunol Immunother. 
2007;56(3):391–396.
 203. Rowe JH, Johanns TM, Ertelt JM, Lai JC, Way SS. Cytotoxic 
T-lymphocyte antigen 4 blockade augments the T-cell response 
primed by attenuated Listeria monocytogenes resulting in more rapid 
clearance of virulent bacterial challenge. Immunology. 2009;128 
(1 Suppl):e471–e478.
 204. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. 
Blockade of CTLA-4 on both effector and regulatory T cell compart-
ments contributes to the antitumor activity of anti-CTLA-4 antibodies. 
J Exp Med. 2009;206(8):1717–1725.
 205. Tuyaerts S, Van Meirvenne S, Bonehill A, et al. Expression of human 
GITRL on myeloid dendritic cells enhances their immunostimulatory 
function but does not abrogate the suppressive effect of CD4+CD25+ 
regulatory T cells. J Leukoc Biol. 2007;82(1):93–105.
 206. Bushell A, Wood K. GITR ligation blocks allograft protection by 
induced CD25+CD4+ regulatory T cells without enhancing effector 
T-cell function. Am J Transplant. 2007;7(4):759–768.
 207. Cohen AD, Diab A, Perales MA, et al. Agonist anti-GITR antibody 
enhances vaccine-induced CD8(+) T-cell responses and tumor immu-
nity. Cancer Res. 2006;66(9):4904–4912.
 208. Wells JW, Cowled CJ, Farzaneh F, Noble A. Combined triggering 
of dendritic cell receptors results in synergistic activation and potent 
cytotoxic immunity. J Immunol. 2008;181(5):3422–3431.
 209. Mackey MF, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interac-
tions in the priming, differentiation, and effector function of helper 
and cytotoxic T cells. J Leukoc Biol. 1998;63(4):418–428.
 210. Ryan CM, Staveley-O’Carroll K, Schell TD. Combined anti-CD40 
conditioning and well-timed immunization prolongs CD8+ T cell 
accumulation and control of established brain tumors. J Immunother. 
2008;31(9):906–920.
 211. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 
is required for T-cell suppression and T regulatory cell activation 
mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 
2010;70(1):99–108.
 212. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade 
reverses the suppression of melanoma antigen-specific CTL by CD4+ 
CD25(Hi) regulatory T cells. Int Immunol. 2009;21(9):1065–1077.
 213. Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ 
T cell responses to antigen in lymph nodes and tissues. J Immunol. 
2007;179(8):5064–5070.
 214. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. Costimula-
tion of CD8 T cell responses by OX40. J Immunol. 2004;172(8): 
4821–4825.
 215. Ruby CE, Yates MA, Hirschhorn-Cymerman D, et al. Cutting edge: 
OX40 agonists can drive regulatory T cell expansion if the cytokine 
milieu is right. J Immunol. 2009;183(8):4853–4857.
 216. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, 
Weinberg AD. OX40 agonist therapy enhances CD8 infiltration 
and decreases immune suppression in the tumor. Cancer Res. 
2008;68(13):5206–5215.
 217. Morris A, Vetto JT, Ramstad T, et al. Induction of anti-mammary 
cancer immunity by engaging the OX-40 receptor in vivo. Breast 
Cancer Res Treat. 2001;67(1):71–80.
 218. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks sup-
pression by regulatory T cells and facilitates tumor rejection. J Exp 
Med. 2008;205(4):825–839.
 219. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. 
Defects in the acquisition of CD8 T cell effector function after priming 
with tumor or soluble antigen can be overcome by the addition of an 
OX40 agonist. J Immunol. 2007;179(11):7244–7253.
 220. Myers L, Lee SW, Rossi RJ, et al. Combined CD137 (4-1BB) and 
adjuvant therapy generates a developing pool of peptide-specific CD8 
memory T cells. Int Immunol. 2006;18(2):325–333.
 221. Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS. 4-1BB 
promotes the survival of CD8+ T lymphocytes by increasing expres-
sion of Bcl-xL and Bfl-1. J Immunol. 2002;169(9):4882–4888.
 222. Ju SA, Lee SC, Kwon TH, et al. Immunity to melanoma mediated 
by 4-1BB is associated with enhanced activity of tumour-infiltrating 
lymphocytes. Immunol Cell Biol. 2005;83(4):344–351.
 223. Laderach D, Movassagh M, Johnson A, Mittler RS, Galy A. 4-1BB 
co-stimulation enhances human CD8+ T cell priming by augmenting 
the proliferation and survival of effector CD8+ T cells. Int Immunol. 
2002;14(10):1155–1167.
 224. Liu S, Breiter DR, Zheng G, Chen A. Enhanced antitumor responses 
elicited by combinatorial protein transfer of chemotactic and costimu-
latory molecules. J Immunol. 2007;178(5):3301–3306.
 225. Shackleton M, Davis ID, Hopkins W, et al. The impact of imiqui-
mod, a toll-like receptor-7 ligand (TLR7L), on the immunogenicity 
of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer 
Immun. 2004;4:9.
 226. Barnetson RS, Satchell A, Zhuang L, Slade HB, Halliday GM. Imi-
quimod induced regression of clinically diagnosed superficial basal 
cell carcinoma is associated with early infiltration by CD4 T cells and 
dendritic cells. Clin Exp Dermatol. 2004;29(6): 639–643.
 227. Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, Radsak MP. 
Transcutaneous immunization with imiquimod is amplified by CD40 
ligation and results in sustained cytotoxic T-lymphocyte activa-
tion and tumor protection. Clin Rev Allergy Immunol. 2007;32(1): 
 57–66.
 228. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immuniza-
tion with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in 
the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. 
J Immunol. 2005;174(12):7676–7683.
 229. Lehner M, Morhart P, Stilper A, et al. Efficient chemokine-dependent 
migration and primary and secondary IL-12 secretion by human 
dendritic cells stimulated through Toll-like receptors. J Immunother. 
2007;30(3):312–322.
 230. Urry Z, Xystrakis E, Richards DF, et al. Ligation of TLR9 induced 
on human IL-10-secreting tregs by 1alpha,25-dihydroxyvitamin 
D3 abrogates regulatory function. J Clin Invest. 2009;119(2): 
387–398.
 231. de Alencar BC, Araujo AF, Penido ML, Gazzinelli RT, Rodrigues MM. 
Cross-priming of long lived protective CD8+ T cells against Trypano-
soma cruzi infection: importance of a TLR9 agonist and CD4+ T cells. 
Vaccine. 2007;25(32):6018–6027.
 232. Haining WN, Davies J, Kanzler H, et al. CpG oligodeoxynucleotides 
alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer 
Res. 2008;14(17):5626–5634.
 233. Fricke I, Mirza N, Dupont J, et al. Vascular endothelial growth factor-
trap overcomes defects in dendritic cell differentiation but does 
not improve antigen-specific immune responses. Clin Cancer Res. 
2007;13(16):4840–4848.
 234. Ko JS, Bukowski RM, Fincke JH. Myeloid-derived suppressor cells: 
a novel therapeutic target. Curr Oncol Rep. 2009;11(2):87–93.
 235. Houben R, Voigt H, Noelke C, Hofmeister V, Becker JC, Schrama D. 
MAPK-independent impairment of T-cell responses by the multikinase 
inhibitor sorafenib. Mol Cancer Ther. 2009;8(2):433–440.
 236. Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy 
on immature myeloid cell and dendritic cells in cancer patients. Cancer 
Immunol Immunother. 2008;57(8):1115–1124.
 237. Bellati F, Napoletano C, Ruscito I, et al. Complete remission of ovar-
ian cancer induced intractable malignant ascites with intraperitoneal 
bevacizumab. Immunological observations and a literature review. 
Invest New Drugs. 2009. [Epub ahead of  print Nov 24].
Open Access Journal of Urology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/open-access-journal-of-urology-journal
The Open Access Journal of Urology is an international, peer-reviewed, 
open access journal publishing original research, reports, editorials, 
reviews and commentaries on all aspects of adult and pediatric urology 
in the clinic and laboratory including the following topics: Pathology, 
pathophysiology of urological disease; Investigation and treatment of 
urological disease; Pharmacology of drugs used for the treatment of 
urological disease. The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.
Open Access Journal of Urology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
141
Update on RCC vaccines
 238. Dawson NA, Guo C, Zak R, et al. A phase II trial of gefitinib (Iressa, 
ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer 
Res. 2004;10(23):7812–7819.
 239. Jermann M, Stahel RA, Salzberg M, et al. A phase II, open-label study 
of gefitinib (IRESSA) in patients with locally advanced, metastatic, 
or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol. 
2006;57(4):533–539.
 240. Andrade Filho PA, Lopez-Albaitero A, Gooding W, Ferris RL. Novel 
immunogenic HLA-A*0201-restricted epidermal growth factor 
receptor-specific T-cell epitope in head and neck cancer patients. 
J Immunother. 2010;33(1):83–91.
 241. Metzler B, Gfeller P, Wieczorek G, Katopodis A. Differential promo-
tion of hematopoietic chimerism and inhibition of alloreactive T cell 
 proliferation by combinations of anti-CD40Ligand, anti-LFA-1, everoli-
mus, and deoxyspergualin. Transpl Immunol. 2008;20(1–2):106–112.
 242. Hsu FJ, Komarovskaya M. CTLA4 blockade maximizes antitumor 
T-cell activation by dendritic cells presenting idiotype protein or 
opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother. 
2002;25(6):455–468.
 243. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 block-
ade and GM-CSF combination immunotherapy alters the intra-
tumor balance of effector and regulatory T cells. J Clin Invest. 
2006;116(7):1935–1945.
 244. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory 
T cells specifically enhances antigen-specific immune responses to 
cancer vaccines. Blood. 2008;112(3):610–618.
 245. Petrausch U, Jensen SM, Twitty C, et al. Disruption of TGF-beta 
signaling prevents the generation of tumor-sensitized regulatory 
T cells and facilitates therapeutic antitumor immunity. J Immunol. 
2009;183(6):3682–3689.
 246. Sanjabi S, Mosaheb MM, Flavell RA. Opposing effects of TGF-beta 
and IL-15 cytokines control the number of short-lived effector CD8+ 
T cells. Immunity. 2009;31(1):131–144.
 247. Kim S, Buchlis G, Fridlender ZG, et al. Systemic blockade of 
transforming growth factor-beta signaling augments the efficacy of 
immunogene therapy. Cancer Res. 2008;68(24):10247–10256.
 248. Castro AG, Neighbors M, Hurst SD, et al. Anti-interleukin 10 receptor 
monoclonal antibody is an adjuvant for T helper cell type 1 responses 
to soluble antigen only in the presence of lipopolysaccharide. J Exp 
Med. 2000;192(10):1529–1534.
 249. Chen G, Liu J, Wang QH, et al. Effects of CD4(+)CD25(+)Foxp3(+)
regulatory T cells on early Plasmodium yoelii 17XL infection in 
BALB/c mice. Parasitology. 2009;136(10):1107–1120.
 250. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory 
cytokine IL-35 contributes to regulatory T-cell function. Nature. 
2007;450(7169):566–569.
 251. Ou X, Cai S, Liu P, et al. Enhancement of dendritic cell-tumor fusion 
vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 
1-MT. J Cancer Res Clin Oncol. 2008;134(5):525–533.
